Home » Interviews » INTERVIEW: Oxford BioDynamics Increased Capacity and 5th Contract
Oxford BioDynamics

INTERVIEW: Oxford BioDynamics Increased Capacity and 5th Contract

Oxford BioDynamics plc (LON:OBD) CEO Christian Hoyer Millar joins DirectorsTalk to discuss contract number 5 in the Immuno Oncology space. Christian also discusses proprietary IP and the increased capacity to take on more work.

Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.